Novynette Plus

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Novynette Plus

Quick Facts

Property Description
Active ingredients Desogestrel (Progestin) and Ethinyl Estradiol (Estrogen)
Form Film-coated tablet
Pharmacological class Combined Hormonal Contraceptive (CHC)
Common use Prevention of pregnancy
Origin Synthetic hormones

Novynette Plus: A Combined Oral Contraceptive (COC)

Novynette Plus is a prescription-only combined hormonal contraceptive, classified under the pharmacological group of oral contraceptives. This synthetic medication is delivered as an oral dosage form, specifically a film-coated tablet, intended for systematic use by women of reproductive potential. The designation as a combined oral contraceptive indicates that the product contains two types of synthetic hormones, offering a coordinated, dual action to manage the reproductive cycle. This method is clinically recognized as one of the most reliable, reversible forms of contraception when used correctly.

Composition and Type: Desogestrel and Ethinyl Estradiol

The active ingredients of the medication are the synthetic progestin Desogestrel and the synthetic estrogen Ethinyl Estradiol (Ethinylestradiol). The formulation is a combination product utilizing these two substances for their combined effect. Desogestrel is classified as a third-generation progestin, a distinction relating to its specific chemical structure compared to older progestin compounds. Novynette Plus is further categorized as a monophasic pill, meaning every active tablet provides a fixed, consistent amount of both the Desogestrel and Ethinyl Estradiol components throughout the designated dosing cycle.

General Purpose: Reliable Pregnancy Prevention

The primary and exclusive function of Novynette Plus is the prevention of pregnancy (contraception). This objective is achieved through the consistent delivery of the synthetic hormones, which establish a hormonal environment that suppresses the body's natural reproductive cycle. By inhibiting the processes required for the release of an egg from the ovary, the medication ensures that the primary reproductive event, ovulation, is prevented, fulfilling its core therapeutic purpose.

What side effects are possible with Novynette Plus?

Possible Side Effects and Safety Information

The safety profile of Novynette Plus (Desogestrel / Ethinyl Estradiol) is defined by officially documented side effects classified by frequency and system-organ class, as detailed in regulatory documents.

Official Adverse Reaction Frequencies

Classification Examples of Effects
Common (≥1/100 to <1/10) Headache, depressed mood, nausea, abdominal pain, breast pain/tenderness, weight increased.
Uncommon (≥1/1,000 to <1/100) Vomiting, diarrhea, migraine, fluid retention, rash, decreased libido.
Rare (≥1/10,000 to <1/1,000) Venous Thromboembolism (VTE), Arterial Thromboembolism (ATE), Hypersensitivity reactions.

Serious Adverse Reactions and Safety Constraints

The most significant, though rare, safety risks documented in official prescribing information relate to the vascular system and the liver. Serious adverse reactions include Venous and Arterial Thromboembolism (e.g., Deep Vein Thrombosis, Pulmonary Embolism, Stroke, Myocardial Infarction) and Hepatic Neoplasia (liver tumors).

Risk patterns documented in regulatory sources specify that the risk of thromboembolism is highest during the first year of use or when restarting treatment after a break of four weeks or longer. Irregular bleeding, such as spotting or breakthrough bleeding, is most frequently observed during the initial three months of use.

Official safety restrictions (contraindications) preclude the use of this medicine in individuals with a history of or current thrombotic events, severe hepatic disease, liver tumors, or certain estrogen-dependent cancers. Furthermore, the label notes a substantially increased cardiovascular risk in women over 35 years of age who smoke. These classifications structure the official understanding of the medicine’s risk profile, strictly adhering to government regulatory standards.

Overdose and Emergency Response

The official regulatory documentation for Novynette Plus, containing desogestrel and ethinyl estradiol, defines the drug's overdose profile primarily through expected clinical signs related to the hormonal components. Acute ingestion of doses higher than prescribed may result in certain specific, documented symptoms.

The key clinical manifestations of overdose reported in official prescribing information are nausea and the occurrence of withdrawal bleeding in females. These signs are generally related to the underlying pharmacological activity but are not typically associated with severe systemic toxicity.

Regarding the acute toxicity profile, regulatory authorities have documented findings concerning accidental ingestion, specifically noting the absence of reported serious ill effects following the acute ingestion of large doses of oral contraceptives by young children. This official assessment establishes a low acute toxicity baseline for this combination product.

In the event of an overdose, the regulatory Overdosage section does not provide explicit, mandated emergency actions or specific procedural instructions for supportive treatment. Since no specific antidote is known, management is understood to be symptomatic and supportive. The regulatory text does not explicitly define specific conditions that require immediate medical attention, based on the low acute toxicity risk reflected in the official record.

Therapeutic Uses of Novynette Plus

What Novynette Plus Treats: Main Uses and Benefits

The primary therapeutic use of Novynette Plus is commonly used for the prevention of unintended pregnancy. As a combined oral contraceptive, it is used to prevent pregnancy, and when taken systematically, it is relevant for managing situations that require systematic reproductive management. This foundational benefit contributes to improved comfort in situations where patients experience a need for reproductive control.

Beyond contraception, this medication is commonly used to help with conditions characterized by periods of heightened symptoms. The medication supports patients during difficult episodes by helping to address symptoms related to physical discomfort, such as severe menstrual cramping (dysmenorrhea), and heavy or irregular menstruation. It is also relevant for easing symptoms associated with heightened physiological activity, such as hormonal acne and cyclic emotional distress. It may also be part of symptomatic management for conditions like endometriosis. This approach helps patients cope more steadily by assisting with maintaining functional stability during symptomatic periods.


Quick Fact: Relief for Pain and Predictability

Property Description
Primary Domain Contraception
Symptom Relief Menstrual pain, heavy bleeding, hormonal acne
Benefit Supports cycle predictability
Clinical Context Systematic cycle management

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Novynette Plus

Official regulatory documentation defines eligibility for Novynette Plus (Desogestrel and Ethinyl Estradiol) based on specific health and physiological status, primarily for women of reproductive potential after menarche.


Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated if a patient has or has a history of certain severe conditions:

  • Thromboembolic Disorders: Presence or history of venous or arterial thromboembolism (VTE/ATE) or known hereditary/acquired thrombophilic conditions.
  • Vascular/Neurological Risk: Uncontrolled severe hypertension, diabetes with vascular damage, or migraine with focal neurological symptoms (aura).
  • Hepatic/Oncology: Severe hepatic disease, liver tumors, or known/suspected malignancies influenced by sex steroids (e.g., breast cancer).
  • Age and Smoking: Women over 35 years of age who smoke are absolutely prohibited from using this medicine.

Restrictions and Special Status

Status Regulatory Classification
Pregnancy Contraindicated in known or suspected pregnancy.
Lactation Not recommended during breastfeeding.
Age Not indicated for use in post-menopausal women.
Postpartum Use should be delayed until at least four weeks after delivery.

Eligibility also requires discontinuation before major surgery or during prolonged immobilization. Use is established only in the post-menarche age group.

What should I know about interactions with other medicines?

Novynette Plus (desogestrel/ethinylestradiol) can interact with several types of medicines, primarily by affecting the metabolism of the contraceptive hormones. The most significant interactions occur with enzyme-inducing products, which speed up the breakdown of the contraceptive steroids (ethinylestradiol and desogestrel metabolites) in the liver. This acceleration can lead to lower hormone levels, resulting in a reduced contraceptive effectiveness and an increased risk of breakthrough bleeding.

Key Interacting Categories

Product Category Example Medicines Interaction Outcome
Enzyme Inducers Rifampicin, Carbamazepine, Phenytoin, Griseofulvin, St John's Wort Significantly reduced contraceptive efficacy.
HIV/HCV Medicines Ritonavir, Nevirapine, Efavirenz Efficacy may be reduced; close monitoring and backup contraception required.
CYP450 Substrates Lamotrigine, Ciclosporin Contraceptive may decrease Lamotrigine levels (risk of seizure) or increase Ciclosporin levels.

If Novynette Plus is co-administered with a strong enzyme inducer, a non-hormonal barrier method of contraception must be used during the treatment and for 28 days after stopping the interacting medicine. Additionally, any severe vomiting or diarrhea occurring within 3 to 4 hours of taking a tablet may compromise absorption, which requires taking an extra tablet immediately to maintain protection. The overall interaction profile emphasises the risk of reduced efficacy and the necessary procedural constraints to ensure contraceptive reliability.

Mechanism of Action

Hormonal Axis Modulation

Novynette Plus utilizes a combination of the progestin desogestrel and the estrogen ethinylestradiol to modulate the hypothalamic-pituitary-ovarian (HPO) axis. Desogestrel primarily acts by binding to and activating progesterone receptors, which in turn inhibits the pulsatile release of gonadotropin-releasing hormone (GnRH). This activity diminishes the secretion of the pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The resulting suppressed levels of FSH and LH lead to the inhibition of follicular development and prevent the ovum's release, establishing an anovulatory state.


Peripheral Tissue Changes

The progestin component also induces structural and functional changes in the cervical mucus, significantly increasing its viscosity. This modification functionally impedes sperm transport through the cervix. Concurrently, the combination of desogestrel and ethinylestradiol induces endometrial hypotrophy and other tissue alterations, decreasing the uterine lining's receptivity to blastocyst implantation. The inclusion of ethinylestradiol stabilizes the endometrial structure, maintaining a predictable hormonal profile.

Dosage and Administration Information

How to Use Novynette Plus: Administration Overview

Novynette Plus is an oral medication that must be taken consistently according to a specific schedule. The administration protocol is based on a 28-day cycle consisting of 21 active tablets and 7 placebo tablets.


Daily Dosing Schedule

Item Instruction Details
Route Swallowed orally with a little water.
Frequency One tablet daily for 28 consecutive days.
Timing Tablets must be taken at approximately the same time each day to maintain effectiveness.

Starting the First Pack

For the first cycle, taking the first tablet on Day 1 of the natural menstrual period (the first day of bleeding) establishes immediate efficacy. Starting between Day 2 and Day 5 of the period requires the use of a non-hormonal barrier method of contraception for the first seven days.


Management of Missed Doses

If a dose is missed, action is determined by the time elapsed since the scheduled dose. There are two specific scenarios:

  • Less than 12 Hours Late: Take the missed tablet immediately, and continue with the next tablets at the usual time. Contraceptive protection is maintained.
  • More than 12 Hours Late: Take the missed tablet immediately (even if it means taking two tablets on the same day). Additional non-hormonal contraception (e.g., condoms) must be used for the following 7 days as contraceptive protection may be reduced.

This continuous daily schedule, defined by time-sensitive dosing and specific starting and missed-dose protocols, forms the procedural basis for using the medicine.

Recent Clinical Evidence

Novynette Plus: Recent Clinical Evidence

Overview of Contraceptive Efficacy

Clinical research has focused on the contraceptive efficacy, cycle control, and safety profile of the low-dose combination drug, Novynette Plus (containing ethinylestradiol and desogestrel). Large-scale clinical trials and observational studies have been conducted to evaluate its performance.

In studies measuring the ability to prevent pregnancy, high contraceptive efficacy was consistently recorded. For example, some clinical trials reported a Pearl Index of 0.00, indicating that no pregnancies occurred among the women using the medication as intended during the study period. Other large cohort studies examining the active ingredients have reported low rates of method failure, confirming the product's primary intended effect.

Cycle Control and Tolerability

Researchers evaluated the effect of the medication on the bleeding pattern and tolerability, which are key factors in user continuation. The evidence base suggests the following outcomes in trial participants:

  • Cycle Regularity: The medication was generally associated with good cycle control, with predictable withdrawal bleeding patterns established over the first few months of use.
  • Bleeding Irregularities: Incidences of irregular bleeding, such as spotting or breakthrough bleeding, were most frequently observed during the initial one to three cycles of use and typically decreased thereafter.
  • Other Observed Effects: Studies also tracked the occurrence of common adverse events typical of low-dose hormonal contraceptives, including headache, nausea, and breast tenderness. The incidence of severe, drug-related side effects was generally low, and the medication was considered to be well-tolerated by most participants.

Consultation with a healthcare professional is necessary to determine treatment suitability.

Frequently Asked Questions (FAQ)

Common questions about Novynette Plus (FAQ)


Q: Are there known food or supplement interactions with Novynette Plus?

Regulatory information indicates that the herbal product St John's Wort is known to reduce the effectiveness of this medicine by speeding up the breakdown of hormones. While food is not often a major concern, some general warnings for combination pills advise caution regarding large amounts of grapefruit juice, which may affect estrogen levels.


Q: Do official sources discuss Novynette Plus's effect on acne?

Official drug documents note that acne may be a reported effect, although the exact incidence is sometimes listed as unknown. For some combination oral contraceptives, improvements in acne are listed as a secondary benefit, but the primary indication for Novynette Plus is contraception.


Q: Is it normal to experience spotting when first starting Novynette Plus?

Official evidence from clinical studies indicates that irregular bleeding, often called spotting or breakthrough bleeding, is frequently observed during the first one to three months of use. This is described as a common adjustment period for the body's cycle while taking the medicine. The evidence suggests that, for many users, this irregular bleeding typically lessens or stops as the body adjusts.


Q: How is Novynette Plus described in comparison to other combination pills regarding its hormonal dose?

Novynette Plus is classified in regulatory documents as a low-dose combined oral contraceptive. It contains a synthetic progestin called desogestrel, which is categorized as a third-generation progestin. This classification relates to the specific amount and type of synthetic hormones used in the formulation compared to older products.


Q: What information is available regarding the cessation of Novynette Plus use?

Regulatory texts indicate that once the medicine is stopped, normal ovarian activity is usually expected to return relatively quickly. The time it takes for an individual's natural reproductive cycle to fully resume may vary slightly from person to person.


Q: Does Novynette Plus contain lactose or other inactive ingredients that people might be concerned about?

Official regulatory documents specifying the medicine's composition state that the tablet core contains lactose monohydrate. Patients who have concerns about specific inactive ingredients often consult the full product information sheet or their prescribing physician.


Q: Are there different instructions for starting Novynette Plus based on a woman's previous contraceptive method?

Official instructions provide distinct, detailed guidance for starting the medicine, depending on the person's prior contraceptive method. Specific protocols exist for switching from another combined pill, a progestin-only pill, or a long-acting method like an injection or implant.


Q: Is Novynette Plus available in different formulations or strengths?

Official documents for this specific medicine typically list only one strength and formulation for the active tablets. This means the dose of the two active hormones, desogestrel and ethinylestradiol, is fixed in the registered product.


Q: Are there any documented long-term studies on the use of Novynette Plus?

The medicine's safety profile is supported by extensive epidemiological and observational data that track the use of combination pills over time. These large-scale studies are essential for determining the frequency of rare, long-term risks, such as venous thromboembolism (VTE).


Q: Can Novynette Plus be used by women in their 40s?

Official warnings state that the medicine must not be used by women over 35 years of age who smoke. For non-smoking women in their 40s, there is no absolute prohibition noted in regulatory documents. Suitability is instead based on a careful assessment of individual cardiovascular risk factors and overall health status.


Q: Is there a maximum age generally associated with the use of Novynette Plus?

Official guidance states that the medicine is contraindicated, meaning it must not be used, in women who are post-menopausal. For women of reproductive potential, age restrictions are tied to smoking status, where use is prohibited for smokers over the age of 35.


Q: Do the side effects of Novynette Plus usually subside over time?

Official documents specifically indicate that irregular bleeding, like spotting, is expected to decrease or resolve after the initial one to three cycles of use. While other common effects like headache or nausea are tracked, the expectation of them subsiding is most often officially noted for the bleeding pattern changes.


Q: What kind of herbal products are officially noted as potentially interacting with Novynette Plus?

Official regulatory documents specifically highlight the herbal product St John's Wort (Hypericum perforatum) as a key interaction. The use of St John's Wort can potentially reduce the contraceptive efficacy of the medicine.


Q: What is considered the duration of effect for Novynette Plus?

The medicine is designed for continuous daily use to maintain a constant level of hormones needed for contraception. To maintain effectiveness, the continuous daily schedule aims to ensure the 24-hour interval between doses is not exceeded, which regulatory information describes as necessary for contraceptive protection.


Q: Is Novynette Plus appropriate for individuals with a history of migraines?

Regulatory documents list a specific type of migraine—migraine with focal neurological symptoms, also known as aura—as an absolute contraindication. This means the medicine must not be used by individuals with this specific condition.


Q: Are there studies that specifically examined the quality of life aspects of using Novynette Plus?

Clinical studies supporting the regulatory file often examine patient-reported outcomes such as tolerability, subjective symptoms, and overall quality of life. These assessments help gauge how the medicine is received by users beyond its primary efficacy.


Q: Does taking Novynette Plus affect the results of any common medical tests?

Official regulatory documents warn that combination oral contraceptives may influence the results of specific laboratory tests. This effect can be seen in tests assessing the function of the liver, thyroid, adrenal, and renal systems, as well as certain plasma protein levels.


Q: What are the official recommendations if a person is traveling across multiple time zones while using Novynette Plus?

Official instructions require the tablet to be taken at approximately the same time each day to maintain effectiveness. When traveling across time zones, the consistent 24-hour interval between doses still needs to be maintained, which typically requires adjusting the intake time. This procedural aspect is defined in official instructions.


Q: What are the implications for using Novynette Plus if someone has liver problems?

Regulatory documents strictly state that the medicine is contraindicated in individuals with severe hepatic disease (severe liver illness) or with a history of liver tumors. These conditions are considered absolute prohibitions to its use.


Q: Is Novynette Plus sometimes prescribed for reasons other than contraception, according to official documentation?

Official documentation lists the prevention of pregnancy (contraception) as the exclusive therapeutic indication for this medicine. Any other use is not officially listed in the regulatory label.


Q: What is the difference between Novynette Plus and a progestin-only pill, according to official descriptions?

Novynette Plus is a combined pill that contains two types of synthetic hormones, estrogen and progestin. This formulation primarily works by inhibiting the release of an egg (ovulation). In contrast, progestin-only pills contain only one hormone type and rely more heavily on effects like thickening cervical mucus.


Q: How does the estrogen component of Novynette Plus compare to other combination birth control pills?

Novynette Plus contains the synthetic estrogen ethinylestradiol. Regulatory classification places it among the low-dose combined pills, referencing the amount of this estrogen component compared to older, higher-dose products.


Q: What are the official statements regarding Novynette Plus and mood changes?

Official regulatory documentation lists depressed mood as a common side effect of the medicine. This symptom is tracked and monitored, as it is a known effect associated with combination oral contraceptives.

How should Novynette Plus be stored and disposed of?

Official Storage and Disposal Requirements

Novynette Plus must be stored and handled according to specific conditions defined in regulatory documents to ensure product stability.

Requirement Condition
Storage Temperature Store at controlled room temperature (typically 15 C to 30 C or 59 F to 86 F).
Protection Keep the medication in the original container, tightly closed, and protect from excess heat, light, and moisture (e.g., do not store in the bathroom).
Child Safety Keep out of the sight and reach of children.
Disposal Dispose of any unused or expired product in accordance with local regulatory requirements. The tablets should not be disposed of via wastewater or regular household waste.

Regulatory documents mandate storing the product in its original packaging to protect the tablets from environmental factors, thereby maintaining their labeled shelf-life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Novynette Plus found in:

A-Z Index: